Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019; 18: 90-98
Диссеминированное поражение мозговых оболочек при рабдомиосаркоме параменингеальной локализации
https://doi.org/10.24287/1726-1708-2019-18-4-90-98Аннотация
Развитие лептоменингеального канцероматоза (ЛМК) – достаточно частое событие при рабдомиосаркоме параменингеальной локализации (РМС ПМ). Однако диагностика и лечение данного вида прогрессирования до сих пор представляют трудности для педиатров и детских онкологов, что связано с малым абсолютным числом больных с РМС ПМ, не позволяющим накопить достаточный клинический опыт, отсутствием патогномоничной клинической картины и стандартизованной специфической терапии. В статье представлены описания трех клинических случаев развития ЛМК при РМС ПМ и обзор литературы, посвященный этой проблеме. Родители пациентов дали согласие на использование информации в научных исследованиях и публикациях.
Список литературы
1. Carli M., Cecchetto G., Sotti G. Soft Tissue Sarcomas In: Pediatric Oncology. R Pinkerton, PN Plowman, R Pieters (Eds). 2004; London. Arnold, 339–70.
2. Miller R.W., Young J.L. Jr., Novakovic B. Childhood cancer. Cancer 1995; 75: 395–405. DOI: 10.1002/1097-0142.
3. Siegel R.L., Miller K.D., Ahmedin J. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7–34. DOI: 10.3322/caac.21551.
4. Yang B.A., Wexler L.H., Meyers P.A., Wolden S.L. Parameningeal Rhabdomyosarcoma: Outcomes and Opportunities. Int J Radiat Oncol Biol Phys 2013; 61–6. DOI: 10.1016/j.ijrobp.2012.08.019
5. Grewal J., Harpreet K., Grewal M.D. Leptomeningeal metastasis Copyright© 2001–2018 MedLink Corporation. All rights reserved.
6. Li Y.-S., Jiang B.-Y., Yang J.-J., Tu H.Y., Zhou Q., Guo W.B. Leptomeningeal meta-stases in non-small cell lung cancer patients with EGFR mutations. Journal of Thoracic Oncology 2016. DOI: 10.1016/j.jtho.2016.06.029.
7. Chan R.C., Wataru W. Parameningeal Rhabdomyosarcoma. Radiology 1979 Apr; 131: 211–4. DOI: 10.1148/131.1.211.
8. Kesari S., Batchelor T.T. Leptomeningeal metastases. Neurol Clin N Am
9. ; 21: 25–66. DOI: 10.1016/s0733-8619(02)00032-4.
10. Gleissner B., Chamberlain M.C. Neoplastic meningitis. Lancet Neurol 2006; 5: 443–52. DOI: 10.1016/s1474-4422(06)70443-4
11. O’Meara W.P., Borkar S.A., Stambuk H.E., Lymberis S.C. Leptomeningeal metastasis. Curr Probl Cancer 2007; 31: 372–424. DOI: 10.1016/j.currproblcancer.2007. 07.001.
12. Siegal T., Lossos A., Pfeffer M.R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44: 1463–9. DOI: 10.1212/wnl.44.8.1463.
13. Chamberlain M.C., Kormanik P.A., Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997; 87: 694–9. DOI: org/10.3171/jns.1997.87.5.0694.
14. Berg S.L., Chamberlain M.C. Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management. Cancer Treat Res 2005; 125: 121–46. DOI: 10.1007/0-387-24199-x_8.
15. Berg S.L., Chamberlain M.C. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 2003; 5: 29–40. DOI: 10.1007/s11912-003-0084-9.
16. Leal T., Chang J.E., Mehta M., Robins H.I. Leptomeningeal Metastasis. Challenges in Diagnosis and Treatment. Current Cancer Therapy Reviews 2011; 7: 319–27. DOI: 10.2174/157339411797642597.
17. Meazza C., Ferrari A., Casanova M. Evolving treatment strategies for parameningeal Rhabdomyosarcoma: the experience of the istituto Nazionale tumori of milan. Accepted 18 June 2004. Published online 4 November 2004 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/hed.20117
18. Harris P., Diouf A., Guilbert F., Ameur F., Letourneau-Guillon L., Ménard C. Diagnostic Reliability of Leptomeningeal Disease Using Magnetic Resonance Imaging. Cureus 2019 Apr 9; 11 (4): e4416. DOI: 10.7759/cureus.4416
19. Ho-Shin Gwak, Sang Hyun Lee, Weon Seo Park, Sang Hoon Shin, Heon Yoo, Seung Hoon Lee. Recent Advancements of Treatment for Leptomeningeal Carcinomatosis. Journal of Korean Neurosurgical Society 2015; 58: 1. DOI: 10.3340/jkns.2015.58.1.1
20. Jorda M., Ganjei-Azar P., Nadji M. Cytologic characteristics of meningeal carcinomatosis. Increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 1998; 55: 181–4. DOI: 10.1001/archneur.55.2.181
21. Bruna J., Gonzalez L., Miro J., Velasco R., Gil M., Tortosa A. Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 2009, 115: 381–9. DOI: 10.1002/cncr.24041
22. Le Rhun E., Preusser M., van den Bent M., Andratschke N., Weller M. How we treat patients with leptomeningeal metastases. ESMO Open 2019. DOI: 10.1136/esmoopen-2019-000507
Pediatric Hematology/Oncology and Immunopathology. 2019; 18: 90-98
Leptomeningeal canceromatosis in patient with parameningeal rhabdomyosarcoma
https://doi.org/10.24287/1726-1708-2019-18-4-90-98Abstract
The development of leptomeningeal carcinomatosis (LC) is quite a frequent event during a rhabdomyosarcoma with parameningeal localization, usually known as a parameningeal rhabdomyosarcoma (PM RMS). However, the diagnosis and treatment of this kind of progression are still difficult for pediatricians and pediatric oncologists due to the small absolute number of PM RMS patients, which makes it impossible to accumulate sufficient clinical experience, as well as due to the absence of a pathognomonic clinical picture and a standardized specific therapy. The article describes 3 clinical cases of LC during PM RMS and provides an overview of existing literature focusing on this problem. Parents patients agreed to use personal data in research and publications.
References
1. Carli M., Cecchetto G., Sotti G. Soft Tissue Sarcomas In: Pediatric Oncology. R Pinkerton, PN Plowman, R Pieters (Eds). 2004; London. Arnold, 339–70.
2. Miller R.W., Young J.L. Jr., Novakovic B. Childhood cancer. Cancer 1995; 75: 395–405. DOI: 10.1002/1097-0142.
3. Siegel R.L., Miller K.D., Ahmedin J. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7–34. DOI: 10.3322/caac.21551.
4. Yang B.A., Wexler L.H., Meyers P.A., Wolden S.L. Parameningeal Rhabdomyosarcoma: Outcomes and Opportunities. Int J Radiat Oncol Biol Phys 2013; 61–6. DOI: 10.1016/j.ijrobp.2012.08.019
5. Grewal J., Harpreet K., Grewal M.D. Leptomeningeal metastasis Copyright© 2001–2018 MedLink Corporation. All rights reserved.
6. Li Y.-S., Jiang B.-Y., Yang J.-J., Tu H.Y., Zhou Q., Guo W.B. Leptomeningeal meta-stases in non-small cell lung cancer patients with EGFR mutations. Journal of Thoracic Oncology 2016. DOI: 10.1016/j.jtho.2016.06.029.
7. Chan R.C., Wataru W. Parameningeal Rhabdomyosarcoma. Radiology 1979 Apr; 131: 211–4. DOI: 10.1148/131.1.211.
8. Kesari S., Batchelor T.T. Leptomeningeal metastases. Neurol Clin N Am
9. ; 21: 25–66. DOI: 10.1016/s0733-8619(02)00032-4.
10. Gleissner B., Chamberlain M.C. Neoplastic meningitis. Lancet Neurol 2006; 5: 443–52. DOI: 10.1016/s1474-4422(06)70443-4
11. O’Meara W.P., Borkar S.A., Stambuk H.E., Lymberis S.C. Leptomeningeal metastasis. Curr Probl Cancer 2007; 31: 372–424. DOI: 10.1016/j.currproblcancer.2007. 07.001.
12. Siegal T., Lossos A., Pfeffer M.R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44: 1463–9. DOI: 10.1212/wnl.44.8.1463.
13. Chamberlain M.C., Kormanik P.A., Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997; 87: 694–9. DOI: org/10.3171/jns.1997.87.5.0694.
14. Berg S.L., Chamberlain M.C. Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management. Cancer Treat Res 2005; 125: 121–46. DOI: 10.1007/0-387-24199-x_8.
15. Berg S.L., Chamberlain M.C. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 2003; 5: 29–40. DOI: 10.1007/s11912-003-0084-9.
16. Leal T., Chang J.E., Mehta M., Robins H.I. Leptomeningeal Metastasis. Challenges in Diagnosis and Treatment. Current Cancer Therapy Reviews 2011; 7: 319–27. DOI: 10.2174/157339411797642597.
17. Meazza C., Ferrari A., Casanova M. Evolving treatment strategies for parameningeal Rhabdomyosarcoma: the experience of the istituto Nazionale tumori of milan. Accepted 18 June 2004. Published online 4 November 2004 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/hed.20117
18. Harris P., Diouf A., Guilbert F., Ameur F., Letourneau-Guillon L., Ménard C. Diagnostic Reliability of Leptomeningeal Disease Using Magnetic Resonance Imaging. Cureus 2019 Apr 9; 11 (4): e4416. DOI: 10.7759/cureus.4416
19. Ho-Shin Gwak, Sang Hyun Lee, Weon Seo Park, Sang Hoon Shin, Heon Yoo, Seung Hoon Lee. Recent Advancements of Treatment for Leptomeningeal Carcinomatosis. Journal of Korean Neurosurgical Society 2015; 58: 1. DOI: 10.3340/jkns.2015.58.1.1
20. Jorda M., Ganjei-Azar P., Nadji M. Cytologic characteristics of meningeal carcinomatosis. Increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 1998; 55: 181–4. DOI: 10.1001/archneur.55.2.181
21. Bruna J., Gonzalez L., Miro J., Velasco R., Gil M., Tortosa A. Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 2009, 115: 381–9. DOI: 10.1002/cncr.24041
22. Le Rhun E., Preusser M., van den Bent M., Andratschke N., Weller M. How we treat patients with leptomeningeal metastases. ESMO Open 2019. DOI: 10.1136/esmoopen-2019-000507
